Hui Yu et al. demonstrated that Orelabrutinib downregulated BTK phospholipase C-g2 and NF-kB signaling pathway to inhibit the proliferation of ABC-DLBCL cell lines (TMD8 and HBL-1) [41], which co-express MYC and BCL2 [42–44]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.